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Second-generation antidepressants, such as the selective serotonin
reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake
inhibitors (SNRIs), are considered first-line treatments for anxiety.
Recent studies in major depressive disorder have suggested that
antidepressants are more effective for severely depressed patients
than for mildly depressed patients [1,2]. As a consequence,
guidelines for the treatment of milder depression have changed.
Little is known, however, about whether this relationship between
baseline severity and antidepressant efficacy also holds for anxiety
disorders.
Objective: To examine the influence of baseline severity of
anxiety on antidepressant efficacy for generalized anxiety disor-
der (GAD), social anxiety disorder (SAD), obsessive-compulsive
disorder (OCD), post-traumatic stress disorder (PTSD), and panic
disorder (PD).
Methods: Data from Food and Drug Administration (FDA)
reviews of approved second-generation antidepressants was
used. All premarketing randomized controlled trials of second-
generation antidepressants for the short-term treatment of an
anxiety disorder were included, with the exception of three trials
with incompatible primary outcomes.
Baseline symptom scores and change in symptom scores were
extracted for placebo and treatment groups in each study. For
PD, remission rates were also extracted. Hedges’ g was calculated
from the change score and its standard deviation for GAD, SAD,
OCD, and PTSD. For 10 trials, data on the standard deviation
or remission rate was missing; multiple imputation was used to
impute these missing data. Mixed-effects meta-regression was
used to investigate the effects of treatment group, baseline severity,
and their interaction on the standardized change from baseline or
the remission rate (for PD only).
Results: Fifty-six trials with a total of 14,710 participants
were included. Placebo effect sizes ranged from 0.49 for OCD
to 1.03 for GAD, while drug effect sizes ranged from 0.83
for OCD to 1.35 for GAD. Increasing baseline severity did not
predict greater improvement in drug groups compared to placebo
groups. Standardized regression coefficients of the interaction
term between baseline severity and treatment group were 0.04
(95% confidence interval −0.13 to 0.20, p = 0.65) for GAD, −0.06
(−0.20 to 0.09, p = 0.43) for SAD, 0.04 (−0.07 to 0.16, p = 0.46) for
OCD, 0.16 (−0.22 to 0.53, p = 0.37) for PTSD, and 0.002 (−0.10
to 0.10, p = 0.96) for PD. For OCD, baseline severity did predict
improvement in both placebo and drug groups equally (b = 0.11,
95% confidence interval 0.05 to 0.17, p = 0.001).
Conclusions: No relationship between baseline severity and
the drug-placebo difference was found for anxiety disorders.
These results suggest that mildly or moderately anxious patients
may experience as much benefit from antidepressants as severely
anxious patients. The size of the drug-placebo difference was
small to moderate; whether these effects may be considered clini-
cally relevant remains a matter of debate. If considered clinically
relevant, however, our results suggest that antidepressants may be
prescribed to anxious patients regardless of symptom severity.
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The aim of this study is to investigate safety and efficacy of
the combination treatment with Clomipramine and Paroxetine in
Obsessive Compulsive Disorder (OCD) resistant to monotherapy
or to other associations of drugs.
OCD is the fourth most common mental disorder in the United
States with an estimated lifetime prevalence of 2.5% and is
identified as a major cause of long-term disability to patients and
their families [1,2]. Clomipramine was the first drug approved to
treat OCD and it is still used as monotherapy with a relatively high
rate of success. However, clomipramine is associated with signif-
icant anticholinergic and other adverse effects, which often make
them a second choice to selective serotonin reuptake inhibitors
(SSRI). Paroxetine, at doses of 40mg/die, resulted effective in
treating acute OCD, while long-term administration showed to be
safe to decrease the rate of relapse [3]. Unfortunately, patients
do not always respond adequately to treatment with a SSRI or
tricyclic antidepressant monotherapy, and augmentation strategies
therefore become necessary. Combination of clomipramine and
paroxetine is based on rationale that both drugs inhibit reuptake
of serotonin. Moreover, the use of two concomitant antidepres-
sants may influence other transporters and/or receptors. An in-
crease in clomipramine plasma concentrations may be induced by
paroxetine inhibition of Cytochrome P2D6 enzymes. Conversely,
clomipramine, which is able to inhibit Cytochrome P2D6 enzymes
as well, might increase paroxetine serum levels. However, most
SSRIs are metabolized by multiple enzymes, so the inhibitor
action of clomipramine may not have a substantial impact [4].
We report on the safety and efficacy of the combination
clomipramine-paroxetine in twenty-four adult patients affected
by resistant Obsessive Compulsive Disorder and treated with the
association of clomipramine and paroxetine, at average doses of
150mg/die and 40mg/die respectively. Efficacy was evaluated
with clinical observation and tolerability/safety was estimated
through Sternbach criteria, identifying at least 3 of 10 of this fea-
tures: mental status changes, agitation, myoclonus, hyperreflexia,
diaphoresis, shivering, tremor, diarrhea, incoordination and fever,
routing out other causes (e.g., infectious, metabolic and substance
abuse) and regarding that no neuroleptic had been started before
the onset of the signs and symptoms listed above [5]. Cardiac
activity and the length of the QTc interval were monitored in
recruited subjects.
Sixteen subjects recruited (66.5%) achieved a moderate/high
improvement in obsessive-compulsive symptoms without any ma-
jor tolerability problem. No patients met Sternbach criteria for di-
agnosis of serotonin syndrome, although eleven patients presented
side effects reported as mild (e.g. dizziness, tremor, dry mouth, di-
aphoresis). One patient had to stop treatment because of lengthen-
ing of QTc interval. Few and mild adverse effects appear to be due
to clomipramine anticholinergic action, rather than the enhancing
on 5-HT function induced by this combination treatment. Five
patients underwent measurement of clomipramine blood levels,
which resulted above the reference range (230–450 ng/ml).
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We retrospectively demonstrated that the combination of parox-
etine and clomipramine may be a safe and effective treatment for
resistant OCD. Controlled, prospective and randomized trials are
needed to confirm our preliminary findings.
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Background: Obsessive-compulsive disorder (OCD) is a de-
bilitating psychiatric condition with a lifetime prevalence of
2−3% [1]. The efficacy of serotonin reuptake inhibitors (SRI) for
obsessive-compulsive disorder (OCD) treatment has been well es-
tablished in controlled studies [2]. Although most patients benefit
from pharmacological treatment, up to 60% may not respond to a
first trial with SRI in effectiveness studies [3]. Riluzole is an anti-
glutamatergic agent that has been associated with improvement of
OCD symptoms in an open-label study of SRI augmentation [4].
From this positive result, it has been hypothesized that other agents
acting on the glutamatergic system could enhance the effect of
the SRI in treatment-resistant OCD patients. N-Acetylcysteine
(NAC), an anti-glutamatergic and anti-oxidative agent, is being
considered as an add-on strategy for treatment-resistant OCD.
The main objective of this study was to determine if NAC is
effective in treatment-resistant OCD patients after 16 weeks of
SRI augmentation.
Methods: We conducted a randomized, double-blind, and
placebo-controlled trial in an OCD-specialized outpatient clinic
from May 2012 and October 2014. Patients were considered
eligible if they: (1) had a DSM-IV primary diagnosis of OCD; (2)
failed to respond to at least one previous adequate pharmacolog-
ical treatment for OCD − defined as the use of a SRI (fluoxetine,
paroxetine, citalopram, escitalopram, fluvoxamine, sertraline or
clomipramine) at the maximum recommended or tolerated dosage
for at least 12 weeks; (3) had a baseline Yale-Brown Obsessive-
Compulsive Scale (Y-BOCS) total score 16 and their OCD
symptoms were of at least moderate severity on the Clinical
Global Impression (CGI) Scale. Of 145 eligible subjects, 40
(mean age= 37.9 years, SD= 10.9; male= 52.5%; mean baseline
Y-BOCS score= 25.1, SD= 3.8; mean number of previous ade-
quate treatments= 3.4, SD= 2.0) were randomized (NAC up to
3000mg per day, n = 18; placebo, n = 22) and 35 completed the
trial. The medications that were in use at the time of randomization
were maintained at the same dose. Independent assessments were
conducted at baseline and at the end of the study. The primary
outcome measure was the mean reduction of initial Y-BOCS
scores. For this analysis, we used repeated measures ANOVA.
Trial registration: clinicaltrials.gov identifier NCT01555970.
Results: Both groups showed a reduction of the baseline
Y-BOCS score (mean= 3.5, SD= 7.1) at week 16, but there was no
significant statistical difference between the two groups: patients
who received NAC had a mean reduction of 4.3 (SD= 7.7) points,
whereas those who received placebo had a mean reduction of 3.0
(SD= 6.8) points (within subjects effect: F = 1.025; p value=0.45).
Conclusions: NAC augmentation of SRI was not different
from placebo in this sample of treatment-resistant OCD patients.
Participant’s severity profile, indicated by the baseline Y-BOCS
scores and the number of previous adequate treatments, might
have influenced the results.
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Purpose of the study: Post-traumatic stress syndrome (PTSD) is
a highly prevalent, yet poorly recognized syndrome characterized
by intense reaction (fear, horror, and helplessness) to extreme
traumatic stressor and it is a highly prevalent (7.8% lifetime rate)
anxiety disorder [1]. Sleep disturbances are hallmark symptoms of
posttraumatic stress disorder (PTSD). Subjective reports of sleep
disturbance indicate that 70−91% of patients with post-traumatic
stress disorder (PTSD) have difficulty falling or staying asleep.
Nightmares are reported by 19−71% of patients, depending on the
severity of their PTSD and their exposure to physical aggression.
Studies of PTSD treatment with sertraline [2] provide evidence
for its efficacy in reducing symptoms and its favorable profile
of side-effects. Nightmares and insomnia in combat-related post-
traumatic stress disorder (PTSD) might be resistant to treatment
with selective serotonin reuptake inhibitors (SSRIs) and benzodi-
azepines.
